DMD and muscular dystrophy: In the preclinical study, locoregional (in limb musculature) and systemic intravenous delivery of a rAAV2/8 vector expressing a canine microdystrophin (cMD1) was effective in restoring dystrophin expression and stabilizing clinical symptoms in 12 treated golden retriever muscular dystrophy (GRMD) dogs (Le Guiner et al., 2017).